Switzerland’s Roivant Sciences has launched a new biotech startup, in collaboration with the Cincinnati Children's Hospital Medical Center, called Aruvant Scien 27 November 2018
Takeda announced on Wednesday that Ninlaro (ixazomib) achieved its primary endpoint in the Phase III TOURMALINE-MM3 trial oriented toward multiple myeloma treat 11 July 2018
Striking results from hemophilia A trials carried out at research institutes in London have been described as potentially “groundbreaking” by the lead investiga 15 December 2017
The pressure to show progress in blood cancers at this year’s American Society of Hematology (ASH) Annual Meeting has been intense, and Janssen has not missed o 12 December 2017
Madrid-headquartered PharmaMar has presented positive results at the American Society of Hematology (ASH) annual meeting in Atlanta, Georgia. 11 December 2017
In the race to be the frontrunner in the CAR-T therapy field, the two companies currently in the lead position look to be mirroring each other’s progress. 11 December 2017
Six-month follow-up data on Kymriah (tisagenlecleucel) will bring relief at Swiss pharma giant Novartis and at other drugmakers developing CAR-T therapies. 11 December 2017
The US branch of Taiwan’s PharmaEssentia has presented follow-up results from a trial of its orphan drug candidate Ropeginterferon alfa-2b at the ongoing Americ 11 December 2017
Both Celgene and Bluebird Bio looked set to open up on Monday morning after they presented updated results from the ongoing CRB-401 Phase I study of bb2121, an 11 December 2017
Tokyo’s Takeda Pharmaceutical and Seattle Genetics presented positive data from the Phase III ECHELON-1 study of Adcetris (brentuximab vedotin) at the American 11 December 2017
In an oral presentation at the ongoing American Society of Hematology (ASH) meeting, Johnson & Johnson’s pharmaceutical arm Janssen has described a new analysis 11 December 2017
Three months after the US FDA put a partial hold on three clinical trials investigating Opdivo combination trials in multiple myeloma, the agency has given Bris 6 December 2017
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.